NRG Oncology Clinical Trial Pipeline: 51 Active Trials, 17 Changes This Month

11 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 8 with minor changes only.

Notable

SYMON · Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

Primary completion pushed from Feb 1, 2027 to Jun 1, 2028

Also in this update: Enrollment reduced: 600 → 486 participants; Study completion pushed from May 1, 2032 to Jun 1, 2033

NRG OncologyNot applicable NCT06279013 Registry history of NCT06279013 on ClinicalTrials.gov (opens the registry)

Oct 23, 2026
Notable

Individualized Treatment · Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Primary completion pushed from Dec 1, 2026 to Jan 1, 2029

Also in this update: Study completion pushed from Dec 1, 2031 to Jan 1, 2034

NRG OncologyPhase 2/3 NCT02135042 Registry history of NCT02135042 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Notable

Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation · Advanced Head and Neck Cancer

Trial status changed: Suspended → Active, Not Recruiting

Also in this update: Final enrollment: 475 participants (planned 1714); Study completion pushed from Feb 9, 2027 to Feb 9, 2032

NRG OncologyPhase 2/3 NCT05050162 Registry history of NCT05050162 on ClinicalTrials.gov (opens the registry)

Oct 23, 2026

Show 8 trials with minor changes only

Minor

Observation or Radiation Therapy · Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Enrollment closed, study ongoing

NRG OncologyPhase 3 NCT03180268 Registry history of NCT03180268 on ClinicalTrials.gov (opens the registry)

Oct 2, 2026
Minor

Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy · High Risk Prostate Cancer

Enrollment increased: 1209 → 1500 participants

Also in this update: Trial sites expanded: 413 → 436 locations

NRG OncologyPhase 3 NCT05946213 Registry history of NCT05946213 on ClinicalTrials.gov (opens the registry)

Oct 23, 2026
Minor

Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Trial sites expanded: 211 → 259 locations

NRG OncologyPhase 3 NCT07097142 Registry history of NCT07097142 on ClinicalTrials.gov (opens the registry)

Oct 23, 2026
Minor

SAMURAI · Addition of Stereotactic Radiation Therapy With Immune Therapy · Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Trial sites expanded: 328 → 348 locations

NRG OncologyPhase 2 NCT05327686 Registry history of NCT05327686 on ClinicalTrials.gov (opens the registry)

Oct 23, 2026
Minor

Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Study completion pushed from Jul 31, 2032 to Jul 31, 2033

NRG OncologyPhase 2 NCT05408845 Registry history of NCT05408845 on ClinicalTrials.gov (opens the registry)

Oct 23, 2026
Minor

Radiation Therapy With or Without Apalutamide · Recurrent Prostate Cancer, the BALANCE Trial

Study completion pushed from Oct 27, 2026 to Mar 10, 2030

NRG OncologyPhase 2 NCT03371719 Registry history of NCT03371719 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026
Minor

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide · Newly Diagnosed Glioblastoma

Study completion pushed from Dec 31, 2026 to Jul 7, 2030

NRG OncologyPhase 2 NCT02179086 Registry history of NCT02179086 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026
Minor

Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation · Advanced Esophageal Cancer and Are Not Candidates for Surgery

Study completion moved earlier from Oct 6, 2030 to Oct 6, 2029

NRG OncologyPhase 1 NCT04391049 Registry history of NCT04391049 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

NRG Oncology clinical trial pipeline

What changed in the last 30 days

SYMON · Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

Individualized Treatment · Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation · Advanced Head and Neck Cancer

Observation or Radiation Therapy · Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy · High Risk Prostate Cancer

Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

SAMURAI · Addition of Stereotactic Radiation Therapy With Immune Therapy · Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Radiation Therapy With or Without Apalutamide · Recurrent Prostate Cancer, the BALANCE Trial

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide · Newly Diagnosed Glioblastoma

Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation · Advanced Esophageal Cancer and Are Not Candidates for Surgery

Active trials by phase

Disease areas by active trials, top 10 of 21

Phase 1		2
Phase 2		9
Phase 2/3		6
Phase 3		30